Indacaterol therapy in moderate-to-severe chronic obstructive pulmonary disease: findings from a single-center primary care cohort

BACKGROUND: Once-daily long-acting β(2)-agonists (LABAs) are an important treatment option, either alone or in combination with other inhaled long-acting bronchodilators in the management of chronic obstructive pulmonary disease (COPD). AIMS/OBJECTIVES: To audit the effectiveness of indacaterol as m...

Descripción completa

Detalles Bibliográficos
Autor principal: Singh, Mukesh P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3862397/
https://www.ncbi.nlm.nih.gov/pubmed/24353411
http://dx.doi.org/10.2147/COPD.S53707

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3862397/
https://www.ncbi.nlm.nih.gov/pubmed/24353411
http://dx.doi.org/10.2147/COPD.S53707

Ejemplares similares